Science 37 Holdings (Science 37 Holdings) Net Income (Continuing Operations) : $-124.65 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Science 37 Holdings's Net Income (Continuing Operations) for the three months ended in Sep. 2023 was $-13.92 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 was $-124.65 Mil.

Science 37 Holdings Net Income (Continuing Operations) Historical Data

The historical data trend for Science 37 Holdings's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Science 37 Holdings Net Income (Continuing Operations) Chart

Science 37 Holdings Annual Data

Trend

Jun20

Jun21

Dec22

Net Income (Continuing Operations)

-0.56

-50.99

Science 37 Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Income (Continuing Operations)	Get a 7-Day Free Trial									-23.53	-66.52	-24.63	-19.58	-13.92

Science 37 Holdings Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-124.65 Mil.

Science 37 Holdings (NAS:SNCE) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Science 37 Holdings Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Science 37 Holdings's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Science 37 Holdings (Science 37 Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709

Website

https://www.science37.com

Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.

Executives

Troy Bryenton	officer: Chief Technology Officer	800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari	officer: Chief Legal Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von	director	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton	officer: Chief Commercial Officer	800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn	director	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp.	10 percent owner	168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc.	10 percent owner	168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari	director	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman	officer: Chief Delivery Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman	director, officer: Chief Executive Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar	officer: Chief Medical Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon	officer: Chief Commercial Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B.	director	PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek	officer: Chief Financial Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc.	10 percent owner	929 NORTH FRONT STREET, WILMINGTON NC 28401-3331